Bringing radiotheranostics
to the world
Our mission is to enhance worldwide patient access to targeted theranostics through the generator-produced radioisotopes: Rhenium-188 and Technetium-99m
Technology
Harnessing the power and versatility of Rhenium-188
to deliver radiotherapies to the world.
Rhenium-188 is a powerful beta-emitting isotope long regarded as an attractive candidate for targeted radionuclide therapy in cancer. Because it can be produced using an on-site generator, Rhenium-188 enables a highly differentiated solution for regions with limited radiopharmacy infrastructure or dispersed populations.
A high-energy (2.12 MeV) beta-emission, maximising damage to the tumour cells
A short half-life of 16.9 hours, suited to the pharmacokinetics of small-molecule delivery systems
Shared chemistry with technetium-99m, the workhorse of nuclear medicine imaging around the world
Ability to be produced from a 188-W (tungsten)-based generator.
Leveraging generator technology
Radiopharmaceuticals based on more common therapeutic radioisotopes (on market or in development) such as lutetium-177 (177Lu) and actinium-225 (225Ac), are typically centrally manufactured in facilities that require significant investment and infrastructure to operate, such as reactors or cyclotrons. By contrast, a generator is a convenient system for on-site production of some commonly-used radionuclides.
Pipeline
An advanced pipeline of targeted radiopharmaceuticals designed to maximise access worldwide.
PSMA
Our story
Rhine Pharma is a product of a research collaboration between Telix and the Heidelberg University Hospital.
In 2021, Telix and Heidelberg University Hospital commenced a collaboration to develop a next-generation theranostic for urologic oncology. The aim was to develop a PSMA-targeting small molecule that could be labelled with either 99mTc for SPECT imaging, or 188Re for radioligand therapy.
The collaboration was successful, with our first compound (RHN001) being discovered and patented. The intellectual property was spun out into a newly-formed company called Rhine Pharma GmbH, with our original German collaborators joining as Rhine’s inaugural Scientific Advisory Board.
In parallel, Rhine Pharma is working with Professor Mike Sathekge and his team at NuMeRI, University of Pretoria, South Africa on a Phase 1/2 clinical trial of RHN001-Dx* and RHN001-Tx* called the RHINO trial.
South African Clinical Trials Registry ID: DOH-27-112024-4693
*RHN001-Dx and RHN001-Tx have not received a marketing authorization in any jurisdiction and are for investigational use only.
Partners
Rhine Pharma is supported by a global network of institutions and organisations striving to make radiopharmaceuticals available to patients all over the world.
NuMeRI
Oncidium Foundation
Telix Pharmaceuticals
Oncobeta GmbH
Team
Jonathan Barlow
Senior Advisor
Frederik Giesel
Scientific Advisory Board
Jens Cardinale
Scientific Advisory Board
Clemens Kratochwil
Scientific Advisory Board
Ken Herrmann
Scientific Advisory Board
News
Rhine Pharma Announces First Patient Dosed with PSMA-Targeted Rhenium-188 in RHINO Trial
Rhine Pharma today announces that the first dose of RHN001-Tx has been administered in the Phase 1/2a ‘RHINO’ investigator-initiated trial (IIT) in men with PSMA-positive prostate cancer.
Telix to Spin Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
Telix today announces the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m(99mTc) and rhenium-188 (188Re).
Telix and Heidelberg University Hospital to Develop Next Generation Theranostics
Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop next-generation theranostic radiopharmaceuticals for urologic oncology…
Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
Telix today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021…
Get in Touch
©2025 Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.
The Telix Pharmaceuticals and Rhine pharma names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.
Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings